Redx Pharma (LON:REDX) announced its quarterly earnings data on Monday. The company reported GBX (7) (($0.09)) EPS for the quarter, missing the Zacks’ consensus estimate of GBX (6.50) (($0.08)) by GBX (0.50) (($0.01)), Digital Look Earnings reports.
Shares of LON REDX opened at GBX 6.80 ($0.09) on Tuesday. Redx Pharma has a one year low of GBX 12 ($0.16) and a one year high of GBX 43 ($0.56).
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Markets Daily and is owned by of Markets Daily. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.themarketsdaily.com/2018/11/20/redx-pharma-redx-announces-earnings-results.html.
Redx Pharma Plc operates as a drug discovery and development company in the United Kingdom. It discovers and develops small molecule drugs for treating cancer and fibrosis. The company is developing RXC004, a porcupine inhibitor for the treatment of pancreatic, biliary, and gastric cancers, as well as melanoma; Pan-RAF inhibitor for colorectal cancer; and SHP2, a protein-tyrosine phosphatase for receptor tyrosine kinase signaling in cancer cells.
Further Reading: Cost of Capital Explained
Receive News & Ratings for Redx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.